Compare AbbVie Inc (ABBV) vs Emerson Electric Co. (EMR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Emerson Electric Co. — how do they compare? AbbVie Inc trades at $253.4 (market cap $449.91B), while Emerson Electric Co. trades at $135.1 (market cap $77.24B). The key difference: AbbVie Inc is far larger — about 5.8× Emerson Electric Co.'s market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | EMR | |
|---|---|---|
Market Cap | $449.91B | $77.24B |
Sector | Health | Industrials |
52-Week High | $261.07 | $161.69 |
52-Week Low | $184.85 | $123.30 |
Enterprise Value | $513.38B | $89.51B |
Dividend Yield | 2.72% | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Emerson Electric (EMR) trades at $137.91, down 0.82% on the day, with a neutral technical signal and mixed earnings history. The company maintains solid profitability with a 52.67% gross margin and 13.35% net margin, though ROE is modest at 3.05%. Recent news highlights collaboration with Aramco on corrosion R&D and positive momentum in its Intelligent Devices segment, while cash flow trends show volatility with a net outflow of $2.04B in 2025.
The outlook is cautiously optimistic, supported by a majority analyst buy rating and a $157.60 consensus price target implying 14% upside. Key risks include fluctuating cash flows, elevated debt levels, and competitive pressures in the industrial automation sector. Earnings growth and segment execution remain critical for sustained stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →
